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Abstract
Purpose AST-120 is used to decrease the abundance of serum
uremic toxins in treatment of chronic kidney disease; howev-
er, it could also adsorb concomitantly administered drugs.
This study aimed to develop a prediction method for drug
interaction between AST-120 and concomitantly administered
drugs based on in vitro dissolution and in vivo absorption
behavior.
Methods Sixty-eight drugs were selected for the analysis. For
each drug, theoretical dissolution (Rd) and absorption (Ra)
rates at estimated dosing intervals (1, 30, 60, 90, 120, and
240 min) were calculated using the Noyes-Whitney formula
and compartment analysis, respectively. The optimal thresh-
olds for Rd and Ra (Rdth and Rath) were estimated by comparing
the results with those of previous drug interaction studies for
six drugs. Four drug interaction risk categories for 68 drugs at
each dose interval were defined according to the indices of
dissolution and absorption against their thresholds.
Results The in vitro dissolution and in vivo absorption behav-
ior of the selected drugs were well fitted to the Noyes-Whitney
formula and one- or two-compartment models. The optimal
Rdth and Rath that gave the highest value of consistency with
the equivalence of drug interaction studies were 90 and 30 %,
respectively. As the dosing intervals were lengthened, the
number of drugs classified into the low-risk categories
increased.
Conclusion A new drug interaction prediction method based
on the pharmacokinetic parameters of drugs was developed.
The new model is useful for estimating the risk of drug inter-
action in clinical practice when AST-120 is used in combina-
tion with other drugs.
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Introduction
Chronic kidney disease (CKD) is a global health problem that
is commonly treated with many different medications. As the
glomerular filtration rate decreases during the progression of
CKD, levels of uremic toxins, such as indoxyl sulfate, in-
crease. Accumulation of uremic toxins appears to contribute
to the progression of CKD and cardiovascular disease [1].
AST-120, an orally administered spherical carbon, decreases
serum uremic toxins by adsorbing them and their precursors
within the gastrointestinal tract [2]. The product of AST-120,
Kremezin® (KUREHA CORPORATION, Japan) was ap-
proved as a drug in Japan in 1991, and subsequently in
Korea and the Philippines, for use in improving uremia symp-
toms and delaying the initiation of hemodialysis in patients
with CKD [3, 4].
AST-120 is a non-specific adsorbent that adsorbs organic
substances with molecular weight less than 1000 [5].
Therefore, AST-120 may adsorb concomitantly administered
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drugs, decreasing their efficacy. Several studies that have ex-
amined drug interaction between AST-120 and concomitant
drugs in healthy subjects have reported that AST-120 signifi-
cantly affected the pharmacokinetics of drugs that were ad-
ministered simultaneously. However, certain dosing intervals
have been reported to avoid drug interaction between AST-
120 and some concomitantly administered drugs [6–10].
Significant changes in pharmacokinetic parameters were ob-
served for metoprolol extended-release tablets, even when
they were administered at a 60-min dosing interval following
AST-120 administration [11]. Therefore, the dosing interval
allowing the interaction between AST-120 and concomitantly
administered medications to be avoided may depend on the
characteristics of the drug and/or formulation. Previous drug
interaction studies did not evaluate the potential effects of
altered dosing intervals on the effectiveness of CKD treat-
ment. In clinical practice, no serious adverse events related
to drug interaction between AST-120 and concomitant drugs
have been reported. However, given the wide variety of drugs
used in the treatment of CKD and the inevitability of the
introduction of new medications and formulations in the fu-
ture, prediction of drug interaction between AST-120 and con-
comitant drugs based on their characteristics and formulation
types may guide clinicians regarding CKD treatment and ad-
vice given to CKD patients regarding drug administration.
Two studies have investigated drug interaction between
oral adsorbents and concomitant drugs in vitro [12, 13].
Although these studies provide useful information on drug
interaction between oral adsorbents and concomitantly admin-
istered drugs, their clinical use is limited because the dissolu-
tion behavior and in vivo absorption behavior of the drugs
were not considered.
The objective of this study was to develop a prediction
method for drug interaction based on the dissolution behavior
and absorption behavior of drugs concomitantly administered
with AST-120 in CKD treatment. In addition, the risk catego-




Drugs that were concomitantly administered with AST-120 in
CKD treatment in 2009 in Japan were surveyed, and 68 drugs,
including those administered to patients with CKD or those
whose interaction with AST-120 has been evaluated, were
selected for the analysis. Information regarding dissolution
tests and pharmacokinetics in humans was obtained from the
Japanese Orange Book [14], package inserts, and the litera-
ture. The doses of the formulations used in the dissolution test
and the doses used in the pharmacokinetic study were
determined according to the following rules: (a) the same dose
was selected for the dissolution test and pharmacokinetic
study; (b) the maximum dose in standard clinical practice in
Japan was selected; (c) when drug interaction study results
were available, the dose used in the study was selected; (d)
when data conforming to rules (a), (b), and (c) were unavail-
able in the public domain, the data for the largest dose reported
in the public domain was selected. The pharmacokinetic data
used for the calculation of ka and Tlaga were obtained from
healthy subjects under fasting conditions, except for data re-
garding the metoprolol extended-release tablet.
Calculation of parameters for drug dissolution
from the dissolution test
The dissolution rate constant (kd) values were calculated ac-
cording to the following procedure. The dissolution rates with
time were read from the dissolution test graphs with the first
fluid (pH 1.2) and the second fluid (pH 6.8) for the dissolution
test (the 16th edition of the Japanese Pharmacopoeia), and
defined as measured values. The dissolution rates were calcu-
lated by the extended Eq. (2) of the Noyes-Whitney formula
(1) and recorded as estimated values (Rd). Next, kd values
where the residual sum of squares of the measured and esti-
mated values at each sampling points were the lowest were
determined using the solver function of Microsoft® Office
Excel 2010. When lag time existed in the dissolution process,
such as for encapsulated formulations and enteric-coated for-
mulations, the time for 1 % dissolution was defined as the lag
time (Tlagd), and the kd value was calculated by the Eq. (3).
Data were excluded from the analysis when complete
dissolution was not achieved in both of the fluids during
the test. When kd values were calculated from both the first
fluid and the second fluid for the Japanese Pharmacopoeia
dissolution test, the higher value was used for drug inter-
action prediction. When complete dissolution was achieved
in only one of the fluids, the obtained value was used for
drug interaction prediction. When Rd was less than 0 %, it
was recorded as 0 %.
dC
dt
¼ kS Cs−Cð Þ ð1Þ
kd ¼ kS
C ¼ Cs 1− exp −kdtð Þf g
Rd %ð Þ ¼ xe 1− exp −kdtð Þf g
ð2Þ
When lag time exists; Rd %ð Þ ¼ xe 1− exp −kd t −T lagd
    ð3Þ
(C, concentration in the fluid; Cs, saturating concentration;
k, apparent rate constant; S, surface area of the formulation; kd,
dissolution rate constant; Rd, dissolution rate; xe, dissolution
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rate in an equilibrium state. The calculation was made only
when xe reached 100 %).
Calculation of the parameters for in vivo drug absorption
from the pharmacokinetic study
The parameters for the absorption rate (Ra) were calculated
according to the following procedure. The plasma concentra-
tions of drugs after oral administration were read from the
graph at each sampling point; after which, pharmacokinetic
parameters were estimated using WinNonlin® (version 6.3,
Certara USA Inc., USA). The one- or two-compartment mod-
el providing the best fit to the plasma concentration data was
chosen visually. Next, Ra (%) values, which represent the per-
centage of the maximum absorption at particular time points
(t) after the administration, were calculated from absorption
rate constant (ka) and lag time (Tlaga), which were estimated
from the pharmacokinetic data using Eq. (4). When Tlaga was
less than 0, it was recorded as 0.When Ra was less than 0 %, it
was recorded as 0 %.
Ra %ð Þ ¼ 100 1−exp −ka t−T laga
    ð4Þ
Evaluation of the predictability of the drug interaction
prediction method
When AST-120 and concomitant drugs are administered at an
interval (concomitant drugs are administered first), the disso-
lution and absorption behavior of the concomitant drugs were
the same as those in a single-drug condition (non-concomitant
administration) until the time of AST-120 administration, be-
cause there was no contact between AST-120 and the drugs
during that time. If Rd and/or Ra are sufficiently high, concom-
itantly administered drugs will be absorbed completely before
they contact AST-120, avoiding drug interaction. Therefore,
we estimated the thresholds of Rd and Ra (Rdth and Rath, re-
spectively) that are required to prevent drug interaction. These
thresholds allow the equivalence and non-equivalence of the
pharmacokinetics of concomitantly administered drugs to be
evaluated.
First, Rd and Ra at the time of AST-120 administration after
concomitant drug administration (dosing interval) in previous
drug interaction studies were calculated (Table 1) [6–11].
Drugs that were administered after AST-120 were excluded
from the analysis. When AST-120 and concomitantly admin-
istered drugs were administered simultaneously, the time (t)
was set as 1 min for the calculation of Rd and Ra. Rdth and Rath
were defined as follows: if Rd ≥ Rdth and Ra ≥ Rath, the predic-
tions were regarded as equivalent.
Pharmacokinetic data was obtained from previous studies
(14 results of 6 drugs) examining drug interaction between
AST-120 and concomitantly administered drugs in healthy
subjects (Table 1). The evaluation of the equivalence of phar-
macokinetic parameters was performed according to the sta-
tistical methods or equivalence evaluationmethods used in the
original studies (Table 1).
After arbitrarily changing the values of Rdth and Rath,
the predictions were regarded as equivalent if both
Rd ≥ Rdth and Ra ≥ Rath. Otherwise, when Rd < Rdth
and Ra < Rath, the predictions were regarded as non-
equivalent. Consistency was evaluated by comparing
the equivalence prediction results with the results of
the drug interaction studies. When Rd < Rdth and
Ra ≥ Rath or Rd ≥ Rdth and Ra < Rath, the evaluation
of the results from the predictions and drug interaction
studies was regarded as non-consistent.
The predictive value of equivalence was calculated by
Eq. (5) for 14 results regarding 6 drugs.
Predictive value %ð Þ
¼ number of consistency
.
number 14ð Þ
of results in previous drug interaction studies
 100 ð5Þ
The optimal Rdth and Rath were defined when the maximum
predictive value was obtained.
Grouping of concomitantly administered drugs
Grouping of the 68 concomitantly administered drugs, which
were selected from the results of the survey conducted in
2009, was performed using a drug interaction predictionmeth-
od. Rd and Ra values were calculated at 1 min (actually simul-
taneous), 30 min, 60 min, and 120 min. Four risk categories
were defined according to the indices of Rd and Ra against
their optimal thresholds (ThRd and ThRa): group 1, Rd ≥ ThRd
and Ra ≥ ThRa; group 2, Rd < ThRd and Ra ≥ ThRa; group 3,
Rd ≥ ThRd and Ra < ThRa; and group 4, Rd < ThRd and
Ra < ThRa.
Results
Calculation of the parameters for in vitro drug dissolution
and in vivo drug absorption
Figure 1 shows comparisons of measured and estimated dis-
solution rates of drugs evaluated in the previous drug interac-
tion studies shown in Table 1 (the comparisons about the other
62 drugs are available as supplemental figure). The results
showed good fitting of Eq. (2) or (3) to the measured data.
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Figure 2 shows comparisons of measured and estimated ab-
sorption rates of drugs evaluated in previous drug interaction
studies. The results showed good fitting to the optimal model.
Table 2 summarizes the calculated parameters of kd, Tlagd, ka,
Tlaga, Rd, and Ra for the drugs. Rd and Ra were calculated for the
dosing interval of each drug (time before administration of AST-
120).
Determination of the optimal ranges ofRdth andRath based
on comparisons between the predictions and drug
interaction study results
The consistency of the equivalence predictions with pharmaco-
kinetic parameters reported in previous drug interaction studies
was evaluated. In the case of amlodipine, Rd and Ra were 14.2
and 1.0 %, respectively (Table 2), when AST-120 was admin-
istered simultaneously with the drug. The prediction was
regarded as non-equivalent when Rdth > 14.2 % and
Rath > 1.0 %. The result of the drug interaction study was
non-equivalent (Table 1); therefore, the prediction was defined
as consistent with the result of the drug interaction study when
Rdth > 14.2 % and Rath > 1.0 %. Similarly, when the Rdth and
Rath values of amlodipine at the 30-, 90-, and 240-min dosing
intervals were >99.0 and >26.8 %, ≤100.0 and ≤60.8 %, and
≤100.0 and ≤91.8 %, respectively (Table 2), the predictions
were consistent. In the same manner, Rdth and Rath for all drugs
and dosing intervals, which showed consistency, were estimat-
ed. The predictive values for all drugs and dosing intervals were






























8 5 mg NS 16 %↓ NE 6
30 min NS 11 %↓ NE
90 min NS NS E









Unknown 5 810 mg 34 %↓ 36 %↓ NE 7
60 min NS NS E






















34 100 mg 30 %↓ 22 %↓ NE 11





12 5 mg NS NS E 9
30 min NS NS E





12 0.25 mg 41 %↓ 33 %↓ NE 10
NS not significant, E equivalent, NE non-equivalent
a Under fasting conditions except for the losartan study, in which a high-fat diet was given 30min before AST-120 administration, and metoprolol ER, in
which a breakfast was given 10 min before AST-120 administration
b For amlodipine, aspirin, and nifedipine, the difference was evaluated as NS when there was no significant difference compared with the control
(administration alone). When there was a significant difference, the percentage of the change was expressed. For losartan, triazolam, and metoprolol
extended-release tablets, the parameters after logarithmic transformation were used. The difference was evaluated as NS when the 90 % confidence
interval of the ratio of the mean compared to the control was within the range of 80 to 125%, or the ratio of the mean compared to the control was within
90 to 111 %. When there was a significant difference, the percentage of the change was expressed
c The equivalence was regarded as E when there was no significant difference in AUCt (or AUC∞) or Cmax. The difference was regarded as NEwhen any
of the parameters was significantly different. For the losartan study in which both the unchanged drug and active metabolite were used, the equivalence
was regarded as E only when the differences were evaluated as NS for both compounds
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examined by varying Rdth and Rath. Figure 3 shows the relation-
ship between the thresholds and the predictive values. The
maximum predictive values were 85.7 % in the range of 84.8
to 95.8 % for Rdth and 21.7 to 41.6 % for Rath.
a) b) c)
d) e) f)
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Fig. 2 Fitting of the in vivo absorption behavior of drugs evaluated in
drug interaction studies using WinNonlin®. a Amlodipine. b Aspirin,
dihydroxyaluminum aminoacetate, and magnesium carbonate (Bufferin
combination tablet). c Losartan. d Metoprolol ER. e Nifedipine. f
Triazolam. Plot: measured value, line: estimated value. The better
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pH 1.2 pH 1.2 pH 1.2
Fig. 1 Fitting of the in vitro dissolution behavior of drugs evaluated in
drug interaction studies to the Noyes-Whitney formula. a Amlodipine. b
Aspirin, dihydroxyaluminum aminoacetate, and magnesium carbonate
(Bufferin combination tablet). c Losartan. d Metoprolol ER. e
Nifedipine. f Triazolam. Plot: measured value, line: estimated value,
Rd.: dissolution rate. The higher kd value was selected from the results
of the dissolution test using the first fluid (pH 1.2) and the second fluid
(pH 6.8) for the dissolution test (the 16th edition of the Japanese
Pharmacopoeia)
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Grouping of concomitantly administered drugs using
ThRd and ThRa
Figure 4 shows a scatter plot with Rd and Ra for 68
drugs concomitantly administered with AST-120 at
1 min (actually simultaneous), 30 min, 60 min, and
120 min. To classify the drugs into different drug
interaction risk categories, we set ThRd and ThRa at 90
and 30 %, respectively, from the range of the maximum
predictive values (Fig. 3). All drugs were classified into
group 4 at a 1-min interval (actually simultaneous). As
the dosing interval was lengthened, the values of Ra and
Rd became greater, while the number of drugs classified
into low-risk categories (groups 1 and 2) increased.
Table 2 Rate constant parameters of drugs investigated in previous human drug interaction studies
















Amlodipine Simultaneous 25.54 3.99 0.00 14.2 0.62 0.00 1.0
30 min 99.0 26.8
90 min 100.0 60.8
240 min 100.0 91.8
Aspirin, dihydroxyaluminum aminoacetate, magnesium
carbonate (Bufferin combination tablet)
Simultaneous 11.00 27.64 0.00 15.3 1.55 0.00 2.6
60 min 100.0 78.8
Losartan 30 min 0.6 10.5 0.00 84.8 1.43 0.33 21.7
60 min 97.7 61.6
Metoprolol ER Simultaneous 1.03 0.76 0.00 0.6 0.11 0.00 0.2
60 min 30.9 10.7
Nifedipine Simultaneous 17.59 11.58 0.00 10.0 2.49 0.28 0.0
30 min 95.8 41.6
120 min 99.8 98.6
Triazolam Simultaneous 14.69 11.08 0.00 8.4 17.34 0.44 0.0
Using the Noyes-Whitney formula, kd1.2 (dissolution rate constant for the first fluid for the dissolution test, pH 1.2) and kd6.8 (dissolution rate constant for
the second fluid for the dissolution test, pH 6.8) were calculated. The higher value was used for the prediction. Tlagd (lag time to 1 % dissolution) and Rd.
(dissolution rate at each dosing interval between AST-120 and concomitant drug administration) were calculated.When AST-120 and the concomitantly
administered drug were administered simultaneously, the time interval was set as 1 min for the calculation
ka (absorption rate constant), Tlaga (lag time in absorption), and Ra (absorption rate compared to total absorption until the time of AST-120 administration)






































































Fig. 3 Relationship between threshold and predictive values ofRd and Ra
The relationships between Rath and Rdth and predictive values for all
drugs and all dosing intervals are shown. Predicted values were
explored by varying the magnitudes of Rdth (threshold value of Rd) and
Rath (threshold value of Ra, the rate relative to the total absorption until the
time of AST-120 administration). The prediction was regarded as correct
when the results for the equivalence of the prediction and the
pharmacokinetic parameters were consistent. a Three dimensional
graph. b Contour graph
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Discussion
In this study, we developed a prediction method for drug in-
teraction based on the in vitro dissolution behavior and in vivo
absorption behavior of drugs concomitantly administeredwith
AST-120 in the treatment of CKD. We examined formulas by
Noyes-Whitney, Hixson-Crowell, and Higuchi and extended
Eqs. (2) and (3) of the Noyes-Whitney formula for the calcu-
lation of in vitro dissolution. The Noyes-Whitney formula was
better fitted to the measured and estimated values (data not
shown). The Noyes-Whitney formula, which is based on the
diffusion equation, had good results when a constant surface
area of the formulation was assumed, suggesting that many
drugs had no significant changes in the surface area of the
formulations during drug dissolution. In addition, fitting of
the pharmacokinetic data using a one- or two-compartment
model was suitable for calculating in vivo absorption.
The relevance of logical prediction of drug interaction
based on calculated dissolution and absorption parameters
and previous drug interaction studies was examined. Given
that previous drug interaction studies investigated pharmaco-
kinetic parameters at different dosing intervals,Rd and Ra were
calculated in this study at each time point; after which, we
estimated the optimal percentages of Rd and Ra at the time of
AST-120 administration for avoiding drug interaction by ex-
amining the prediction values (the consistency between the
equivalent/non-equivalent percentages given by the prediction
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Fig. 4 Changes in risk group classification according to dosing interval.
Rd: dissolution rate, Ra: absorption rate relative to total absorption until
the indicated time point. a 1 min (actually simultaneous). b 30 min. c
60 min. d 120 min. Rd and Ra were plotted. The number (n) of drugs
classified into each group when threshold values of Rd and Ra were set as
90 and 30 %, respectively, is shown. 1, amlodipine; 2, aspirin,
dihydroxyaluminum aminoacetate, magnesium carbonate (Bufferin
combination tablet); 3, losartan; 4, metoprolol ER; 5, nifedipine; 6,
triazolam; 7, allopurinol; 8, ambroxol; 9, ambroxol ER; a, arotinolol; b,
aspirin (Bayaspirin); c, atenolol; d, atorvastatin; e, azosemide; f,
bacampicillin; g, benidipine; h, betaxolol; i, brotizolam; j, cefcapene
pivoxil; k, cefdinir; l, celiprolol; m, cetirizine; n, clarithromycin; o,
clonidine; p, clotiazepam; q, cyclosporine; r, digoxin; s, dilazep; t,
enalapril; u, epalrestat; v, epinastine; w, etizolam; x, etodolac; y,
famotidine; z, furosemide; A, glibenclamide; B, guanabenz; C,
ibuprofen; D, imidapril; E, indapamide; F, isosorbide; G, lansoprazole;
H, levofloxacin; I, lisinopril; J, loxoprofen; K, metformin; L, metoprolol;
M, naftopidil; N, nateglinide; O, nicorandil; P, nilvadipine; Q,
omeprazole; R, perindopril; S, pioglitazone; T, pravastatin; U, pro-
pranolol ER; V, rabeprazole; W, rebamipide; X, sodium ferrous
citrate; Y, tamsulosin ER; Z, temocapril; δ, ticlopidine; ζ, tizanidine; θ,
torasemide; λ, trandolapril; π, trichlormethiazide; σ, warfarin; ϕ,
zolpidem
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and Rath. The results showed that the optimal ranges of Rdth
and Rath were 84.8 to 95.8 % and 21.7 to 41.6 %, respectively.
The results demonstrated that the prediction value of the drug
interaction prediction method was as high as 85.7 %.
Here, we demonstrated that our prediction model has rele-
vance to the drug interaction study results. Subsequently, Rd
and Ra of 68 drugs concomitantly administered with AST-120
at 1 min (actually simultaneous), 30 min, 60 min, and 120 min
were calculated. By comparing these values with the thresh-
olds (ThRd = 90 %, ThRa = 30 %), the drugs were classified
into four risk categories. Group 1 was the lowest risk category,
where both Rd and Ra were above the threshold levels, indi-
cating that both dissolution and absorption were rapid. In
group 2, Rd was below each threshold level, while Ra was
above each threshold level, indicating that dissolution was
slow while absorption was rapid, posing a relatively lower
risk of adverse effects on the pharmacokinetics and efficacy
of drugs in this group. In group 3, Rd was above each thresh-
old level, while Ra was below each threshold level, indicating
that dissolution was rapid while absorption was slow, posing a
risk of adsorption of the active substance to AST-120 before
its absorption, which warrants attention. Group 4 was the
highest risk category. In this group, bothRd and Ra were below
each threshold level, indicating slow dissolution and absorp-
tion, as well as the greatest risk of drug interaction. All drugs
were classified into group 4 at 1-min interval (almost simul-
taneous). As the dosing interval was lengthened, the values of
Ra and Rd became greater, while the number of drugs classi-
fied into the lowest risk category (groups 1 and 2) increased.
For example, allopurinol was classified into group 3 at a 30-
min dosing interval, while it was classified into group 1 at
dosing intervals of 60 min or longer. These results suggest
that the detrimental effects of drug interaction between AST-
120 and concomitantly administered drugs on pharmacokinet-
ics and drug efficacy can be reduced by increasing dosing
intervals. In addition, ambroxol hydrochloride, an extended-
release capsule, was classified into group 4 at all dosing inter-
vals. The preferable dosing interval to avoid the risk of drug
interaction varies with the individual drug and is determined
by the dissolution and absorption characteristics. Many
extended-release formulations were classified into the high-
risk categories; therefore, clinicians should pay attention to
drug interaction when using such formulations with AST-120.
Two studies have investigated drug interaction between
oral adsorbents and concomitantly administered drugs
in vitro [12, 13]. Although these studies provide useful
information on drug interaction between oral adsorbents
and concomitantly administered drugs, their clinical use
is limited because the dissolution behavior and absorption
behavior of the drugs were not considered. Our present
prediction method is a totally new approach because it
considered the dissolution and absorption behaviors of
concomitantly administered drugs used in clinical practice.
Thus, the risk of drug interaction is likely to be avoided by
estimating the minimum dosing intervals between AST-
120 and concomitantly administered drugs based on our
risk classification system and the dissolution and absorp-
tion rate thresholds. In addition, this prediction method can
be performed using information available in the public do-
main. Our prediction method is a useful approach for esti-
mating the potential of drug interaction for many drugs that
are concomitantly administered with AST-120 in CKD
treatment.
A considerable limitation of this study was that our pre-
diction method was not based on original experimental
data but on reliable in vitro and in vivo data obtained from
third-party sources. Although our prediction method could
be useful for clinical pharmacologists and clinicians be-
cause it utilizes only information available in the public
domain, the new method should be experimentally validat-
ed in the future. Moreover, evaluation of the relationship
between our prediction method and the other prediction
method could also be important for the validation. The
adsorbent characteristics of AST-120 were not considered.
Considering that the effects of adsorbents on the pharma-
cokinetics of concomitantly administered drugs are small
when the amount/rate of adsorption is small, a classifica-
tion system incorporating factors related to adsorbents may
be more useful. When a drug has poor solubility, but a high
kd value (kd refers to the time required to reach dissolution
equilibrium), prediction of drug interaction is difficult.
Classical physicochemical properties such as molecular
mass, water solubility, logP/D, and dissociation constant
(pKa) might be useful to modify our prediction method.
Furthermore, the validity of the prediction method in this
study remains to be confirmed, because our method was
based on a limited number of drug interaction study results.
Further drug interaction studies are required to improve the
accuracy of prediction.
The present study provides a newly developed drug in-
teraction prediction method based on the pharmacokinetic
parameters of drugs. Although monitoring of the blood
concentration and effectiveness of concomitantly adminis-
tered drugs is required for accurate predictions, drug inter-
action prediction based on the characteristics of drugs and
formulations is useful for estimating the risk of drug inter-
action in clinical practice when AST-120 is used in com-
bination with other drugs.
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